From Nasdaq.: 2024-05-20 02:21:27

AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs) to support its global ADC portfolio. The facility will cover the full manufacturing process for ADCs and aims to be operational by 2029. ADCs are cancer treatments that deliver potent agents directly to cancer cells through antibodies. This will be AstraZeneca’s first end-to-end ADC production site. The company will work on green solutions to ensure zero carbon emissions from the facility’s first day. AstraZeneca has a broad portfolio of in-house ADCs with six ADCs in the clinic and more in preclinical development.

Source: rttnews.com



Read more at Nasdaq.: AstraZeneca To Build $1.5 Bln Manufacturing Facility In Singapore For Antibody Drug Conjugates